Besse, B., Subbiah, V., Curigliano, G., Bowles, D. W., Doebele, R. C., Mansfield, A. S., Baik, C. S., Lopes, G. D. L., Paz-Ares, L., Taylor, M. H., Tan, D. S., Alonso, G., Gadgeel, S. M., Kalemkerian, G. P., Ou, S. I., Wekken, A. J. V. D., Becerra, C. R., Evangelist, M., Griesinger, F., Liu, S. V., Lou, Y., Mazières, J., Melear, J. M., Narang, M., Saxena, A., Thomas, M., Wang, S., Thomassen, A., Lee, D. H., Kim, D., Gainor, J. F. (2026). Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01489